As of close of business last night, BioXcel Therapeutics Inc’s stock clocked out at $3.10, up 0.98% from its previous closing price of $3.07. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 1080073 shares were traded.
Ratios:
To gain a deeper understanding of BTAI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.45 and its Current Ratio is at 2.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 16 when Mehta Vimal sold 30,000 shares for $20.18 per share. The transaction valued at 605,501 led to the insider holds 39,903 shares of the business.
Mehta Vimal sold 30,000 shares of BTAI for $646,226 on Jun 15. The CEO and President now owns 39,903 shares after completing the transaction at $21.54 per share. On May 22, another insider, Mehta Vimal, who serves as the CEO and President of the company, sold 6,500 shares for $25.79 each. As a result, the insider received 167,641 and left with 37,294 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 93.27M and an Enterprise Value of 103.84M. For the stock, the TTM Price-to-Sale (P/S) ratio is 75.95. Its current Enterprise Value per Revenue stands at 83.61 whereas that against EBITDA is -0.52.
Stock Price History:
Over the past 52 weeks, BTAI has reached a high of $32.87, while it has fallen to a 52-week low of $1.91. The 50-Day Moving Average of the stock is 3.0246, while the 200-Day Moving Average is calculated to be 7.5401.
Shares Statistics:
It appears that BTAI traded 1.55M shares on average per day over the past three months and 5.93M shares per day over the past ten days. A total of 28.15M shares are outstanding, with a floating share count of 21.20M. Insiders hold about 30.22% of the company’s shares, while institutions hold 30.85% stake in the company. Shares short for BTAI as of Jan 31, 2024 were 2.46M with a Short Ratio of 1.58, compared to 2.97M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.08% and a Short% of Float of 28.43%.
Earnings Estimates
As of right now, 9 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.61 and a low estimate of -$1.23, while EPS last year was -$1.95. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.86 and low estimates of -$1.04.
Analysts are recommending an EPS of between -$5.42 and -$6.63 for the fiscal current year, implying an average EPS of -$6.06. EPS for the following year is -$2.47, with 9 analysts recommending between -$1.45 and -$4.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $710k. It ranges from a high estimate of $2M to a low estimate of $300k. As of the current estimate, BioXcel Therapeutics Inc’s year-ago sales were $238k, an estimated increase of 198.30% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $550k, an increase of 167.00% less than the figure of $198.30% in the same quarter last year. There is a high estimate of $600k for the next quarter, whereas the lowest estimate is $500k.
A total of 8 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $3M, while the lowest revenue estimate was $1.2M, resulting in an average revenue estimate of $1.69M. In the same quarter a year ago, actual revenue was $375k, up 350.70% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $4.31M in the next fiscal year. The high estimate is $10M and the low estimate is $1.9M. The average revenue growth estimate for next year is up 155.00% from the average revenue estimate for this year.
